Skip to main content
International Journal of Bipolar Disorders
Fig. 2 | International Journal of Bipolar Disorders

Fig. 2

From: Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

Fig. 2

TEAEs occurring in ≥ 5% of patients during the AOM 400 maintenance phase, by enrollment source. TEAEs displayed from most common overall at top to least common overall at bottom, displayed as percent incidence in de novo and rollover patients. AOM 400 = aripiprazole once-monthly 400 mg; TEAE treatment-emergent adverse event, URTI upper respiratory tract infection

Back to article page